Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now